Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the recipient of a significant increase in short interest in June. As of June 15th, there was short interest totalling 24,150,000 shares, an increase of 19.6% from the May 31st total of 20,200,000 shares. Based on an average daily trading volume, of 788,600 shares, the short-interest ratio is currently 30.6 days. Currently, 20.4% of the shares of the stock are sold short.

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC lifted its holdings in Lyell Immunopharma by 9.3% in the 1st quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after buying an additional 4,170 shares in the last quarter. Profund Advisors LLC boosted its holdings in Lyell Immunopharma by 20.0% in the third quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock valued at $108,000 after purchasing an additional 12,225 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after purchasing an additional 14,229 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in Lyell Immunopharma during the 4th quarter worth approximately $31,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Lyell Immunopharma by 67.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 48,855 shares of the company’s stock valued at $109,000 after purchasing an additional 19,718 shares in the last quarter. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Trading Down 4.4 %

LYEL traded down $0.07 during trading on Tuesday, hitting $1.51. 934,752 shares of the company’s stock were exchanged, compared to its average volume of 1,033,032. Lyell Immunopharma has a 1 year low of $1.18 and a 1 year high of $3.41. The stock has a 50 day moving average price of $2.36 and a 200 day moving average price of $2.23. The firm has a market cap of $384.96 million, a P/E ratio of -1.68 and a beta of -0.52.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. Analysts forecast that Lyell Immunopharma will post -0.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LYEL has been the subject of a number of research reports. Bank of America cut their target price on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, June 27th. HC Wainwright restated a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Lyell Immunopharma in a research report on Thursday, June 27th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.